Alicia Morgans

@CaPsurvivorship

Physician, researcher, mom; passionate about improving the lives of men and women with cancer. Views are my own.

Vrijeme pridruživanja: prosinac 2016.

Tweetovi

Blokirali ste korisnika/cu @CaPsurvivorship

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CaPsurvivorship

  1. proslijedio/la je Tweet
    23. ruj 2019.

    Fibroblast growth factor receptor 3 alterations and response to PD-1/PD-L1 blockade in patients with metastatic urothelial cancer. and discussion on UroToday now.

    Poništi
  2. 21. ruj 2019.

    Outstanding talk by at the University of Minnesota’s Prostate Cancer Symposium. Thank you for making treatment decisions so clear for us!

    Poništi
  3. 10. ruj 2019.

    So honored to be involved with and to participate in this year! Thanks to and for talking about the event and men’s health last night!

    Poništi
  4. 12. srp 2019.

    Thank you all for providing a framework for PRO research in oncology. Standardizing a robust research approach is the first step in making data interpretable and useful to the millions of men and women dealing with cancer treatment decisions each day.

    Poništi
  5. 29. lip 2019.

    The things that matter to kids likely matter to all of us. Let’s be kinder, enjoy time together, get to the beach, and definitely eat more ice cream. Life can be bigger and better. Take small steps.

    Poništi
  6. 3. lip 2019.

    One of the clearest minds in the field, shares his insights with brilliance and compassion. I have no doubt we will continue to move the needle with him in our midst.

    Poništi
  7. 3. lip 2019.

    Completely agree with you . Hoping you’ll join the charge and help us educate, anticipate, and create guidelines to ensure the best balance of efficacy and toxicity. Rapid identification of these complications is still too late for some.

    Poništi
  8. 2. lip 2019.

    If you missed it, be sure to watch virtual meeting review what we can and cannot conclude after hearing the ENZAMET outcomes. As always, excellent work.

    Poništi
  9. 2. lip 2019.

    ⁦”Disparities May Be exacerbated by the increasing focus on precision medicine.” ⁩ If we don’t include racially diverse patients in genomic testing, we are not able to precisely target the variants in minority populations. Inclusion is key.

    Poništi
  10. 2. lip 2019.

    ⁩ outlines the challenges of disparities in prostate cancer care and trials in the US, including a framework for progress.

    Poništi
  11. 2. lip 2019.

    Silke Gillessen kicks off the prostate cancer disparities session in S100a, highlighting differences in access between and within countries. Lots of work to be done!

    Poništi
  12. 2. lip 2019.

    Neha Vapiwala delivers a comprehensive review of approaches to oligometastatic prostate cancer, injecting hope and strong scientific rationale into the process.

    Poništi
  13. 2. lip 2019.

    ⁩ reminds us of the benefits of slowing oligoprgression in prostate cancer. Change the natural course of the disease, improve outcomes.

    Poništi
  14. 2. lip 2019.

    Join us in B1 with ⁦⁩ to review the latest data guiding treatment of oligometastatic prostate cancer! Bright and early!

    Poništi
  15. 1. lip 2019.

    Julie Graff artfully walks us through abstracts in the poster discussion

    Poništi
  16. 1. lip 2019.

    Scott Williams implores us to prepare for the PSMA tsunami by designing smart trials to study the effects and populations most likely to benefit.

    Poništi
  17. proslijedio/la je Tweet
    1. lip 2019.

    Looking forward to being part of (an otherwise) great panel in S406 shortly - what do people think about when choosing and sequencing treatments for , in an era where several therapies are now approved for M0 CRPC?

    Poništi
  18. 1. lip 2019.

    Mark Fleming, Dana Rathkopf, Fred Saad, and Ian Davis present their diverse views on the complicated treatment of nmCRPC and downstream effects of treatment. Join the tumor board !

    Poništi
  19. 31. svi 2019.

    Excellent review of negative trial that still enlightens - don’t use abi and enza simultaneously, but always include additional critical questions when designing studies. Alliance again demonstrates correlation between rPFS and OS despite neg study.

    Poništi
  20. 31. svi 2019.

    Bertrand Tombal shares PEACE-3 experience - mandating bone health treatments resulted in a large reduction in SSE, improving patient outcomes with standard of care approach.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·